Virtus Advisers LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Virtus Advisers initiated a 14,294-share position in ANI Pharmaceuticals valued at approximately $1.18 million. Institutional investors and hedge funds collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in EPS and $266.04 million in revenue, with revenue up 25.8% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $105.83, although several firms recently reduced their targets or downgraded the stock to “Hold.”

Virtus Advisers LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 14,294 shares of the specialty pharmaceutical company's stock, valued at approximately $1,183,000. Virtus Advisers LLC owned about 0.06% of ANI Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Penn Capital Management Company LLC boosted its holdings in ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company's stock valued at $10,858,000 after acquiring an additional 131,030 shares during the last quarter. Vanguard Group Inc. raised its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company's stock worth $103,022,000 after purchasing an additional 27,598 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new stake in ANI Pharmaceuticals during the 4th quarter worth about $2,487,000. Artemis Investment Management LLP acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $1,706,000. Finally, CenterBook Partners LP acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $1,518,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $77.32 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of 16.66 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The stock's 50-day moving average price is $80.48 and its two-hundred day moving average price is $78.91. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analysts' expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals's revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ANIP. Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research report on Monday, August 10th. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group lowered their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $105.83.

Insider Activity

In other news, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president directly owned 75,534 shares of the company's stock, valued at $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Thomas Haughey sold 2,000 shares of the business's stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the transaction, the director directly owned 38,878 shares of the company's stock, valued at $3,144,452.64. This trade represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,987 shares of company stock worth $1,546,405 in the last ninety days. Company insiders own 8.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source